Alimera Sciences, Inc.
ALIM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 49.2% | -8.3% | 16.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 75.7% | 85.3% | 88.1% | 86.3% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -1.4% | -17.5% | 6.9% | 5.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -24.9% | -33.5% | -7.4% | -10.5% |
| EPS Diluted | -0.79 | -2.59 | -0.66 | -1.04 |
| % Growth | 69.5% | -292.4% | 36.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |